Navidea Biopharmaceuticals To Collaborate With University of Alabama at Birmingham On Clinical Study Evaluating The RIGS™ Monoclonal Antibody Targeting Agent
Published: Nov 26, 2013
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will collaborate with investigators at the University of Alabama at Birmingham (UAB) on a clinical study to evaluate the safety and activity of a radiolabeled, humanized monoclonal antibody (Mab) from its RIGS™ Monoclonal Antibody Targeting technology.
Help employers find you! Check out all the jobs and post your resume.